RecruitingNCT06927648
CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA
Sponsor
AstraZeneca
Enrollment
130 participants
Start Date
Oct 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.
Eligibility
Min Age: 19 Years
Inclusion Criteria2
- Patients eligible for and treated with the study drug according to the approved label in South Korea
- Patients who provide signed and dated written informed consent, either personally or through a legally acceptable representative.
Exclusion Criteria2
- Participation in any interventional trial during the treatment of the study drug
- Other off-label indications according to the approved label in South Korea
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06927648
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location